Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula I compound and pharmaceutical compositions comprising Formula I compounds.

Abstract: Various aspects of the disclosure relate to a tracheal implant comprising (a) a trachea processed to comprise one or more incisions providing a helical configuration to the processed trachea; and (b) a subject-specific synthetic support.

Abstract: Provided herein is a method of diagnosing and treating a subject suffering from atopic dermatitis (AD), the method comprising: (a) obtaining a skin biopsy from a subject suspected of suffering from AD; (b) determining a level of RNA expression in the skin biopsy of genes selected from the 89ADGES gene panel; (c) comparing the determined level of RNA expression of the selected genes to the level of RNA expression of the selected genes in a reference sample comprising RNA expression products from normal healthy skin cells; (d) diagnosing the subject as suffering from AD when specific genes are up-regulated compared to the reference sample and when specific genes are down-regulated compared to the reference sample; and (e) treating the subject with a therapy effective for the treatment of AD. Methods of managing treatment of a subject suffering from AD are also provided.

Abstract: A method of characterizing nanovesicles is disclosed. The method involves entrapping nanovesicles such as exosomes and sensing the dielectric properties of the exosomes using an electrical impedance sensing device. The method can distinguish exosomes based on different membrane compositions, different cellular origins, different size distribution and/or different cytosolic compositions.

Abstract: A device (100) for sensing a first analyte in sweat on skin includes an analyte-specific sensor (120) for sensing the first analyte and an active sweat coupling component (130) for transporting at least one sweat sample inside the device (100) and into fluid communication with the analyte-specific sensor (120). A method of sensing a first analyte in sweat on skin includes actively transporting at least one sweat sample into fluid communication with an analyte-specific sensor (120) for sensing the first analyte using an active sweat coupling component (130) and sensing the first analyte using the analyte-specific sensor (120).

Abstract: Inhibitors of miRNA-128 capable of promoting cardiomyocyte mitotic cell proliferation and methods effective for regeneration of heart tissue.

Abstract: A method for motion correction of Magnetic Resonance (MR) images is provided. The method includes acquiring a k-space dataset for an object using an MR scanner, detecting or identifying corrupted k-space data from the acquired k-space dataset, extracting the corrupted k-space data from the acquired k-space dataset, recovering the corrupted k-space data, combining uncorrupted k-space data of the acquired k-space dataset with the recovered k-space data to form a full k-space dataset, and reconstructing an image for the object based on the full k-space dataset. A magnetic resonance imaging system for correcting corrupted k-space data of an entire k-space dataset is also provided.

Abstract: Systems, methods, and computer program products for remaining useful life prediction. Operational data is collected from a test machine until a component fails, and a training dataset generated from the operational data. The training dataset is used to define and validate a prediction model. Operational data received from one or more field machines is provided to the prediction model. The prediction model then predicts the remaining useful life of the component of the field machine. To reduce the time-to-failure of the component in the test machine, the component may be repeatedly subjected to an accelerated wear cycle. The prediction model may be defined by extracting features from the training dataset. Like features may be extracted from the field dataset and provided to the prediction model as part of the prediction process. The operational data received from the field machines may be used to generate an updated prediction model.

Abstract: A novel ROS-responsive prodrug is provided. The prodrug utilizes a unique modified oxalate linker conjugated to 4-aminophenol, which can enhance the reaction kinetics for intracellular ROS within tumor tissues while keeping the modified oxalate backbone stable with amide bond under very low ROS level.

Abstract: An augmented neuromuscular training system and method for providing feedback to a user in order to reduce movement deficits associated with injury risk, prior injury or disease pathology.

Abstract: The present invention is a novel blood or plasma panel with utility in assessing chronic liver disease severity in a point-of-care setting. The scoring system exhibits 97.2% correlation to previously assigned Child Pugh scores and does not require clinical assessment beyond laboratory testing.

Abstract: A novel composition is disclosed comprising the complex avobenzone-calix[8]-PO3H2. In another embodiment, the present invention is a sunscreen composition comprising the complex avobenzone-calix[8]-PO3H2 and a cosmetically acceptable carrier.

Abstract: A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

Abstract: A one pot synthesis of a mixed macrocycle of resorcinol and pyrogallol is disclosed using an acidic catalyst by conventional as well as by microwave assisted methods. Compared with traditional synthesis, the microwave mediated tactic provides a simple, greener route and affords higher compound yields in a shorter period. Moreover, the catalyst can be efficiently reused without any loss in activity.

Abstract: A sweat sensor device (200) with analytical assurance includes at least one sensor (220) for detecting a first analyte, and at least one calibration medium (270) containing at least the first analyte. When the first analyte in the at least one calibration medium (270) comes into contact with the at least one sensor (220), the calibration medium (270) provides a calibration of the at least one sensor (220). A sweat sensor device (200) may further include a carrier (240) having at least one aperture (220a) and a reservoir (254) for storing the at least one calibration medium (270). The at least one aperture (220a) provides fluidic access to the at least one sensor (220) from the reservoir (254).

Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula I compound and pharmaceutical compositions comprising Formula I compounds.

Abstract: Systems and methods for the gas-phase production of carbon nanotube (CNT)-nanoparticle (NP) hybrid materials in a flow-through pyrolytic reactor specially adapted to integrate nanoparticles (NP) into CNT material at the nanoscale level, and the second generation CNT-NP hybrid materials produced thereby.

Abstract: A carbon nanotube-based reference electrode and an all-carbon nanotube microelectrode assembly for electrochemical sensing and specialized analytics are disclosed, along with methods of manufacture, and applications including detection of ionic species including heavy metals in municipal and environmental water, monitoring of steel corrosion in steel-reinforced concrete, and analysis of biological fluids.

Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying two or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of two or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

Abstract: Methods and system of using a target-binding aptasensor to determine a concentration of a target in a media may include dispensing target in the media, applying an intermittent pulse amperometry (“IPA”) waveform to the target-binding aptasensor in the media to sense the target, determining a reference point of the target-binding aptasensor to set a baseline level corresponding to the reference point, and determining the concentration of the target in the media based on the baseline level of the reference point.